Currently, Dengvaxia is the only vaccine developed against the DENV, and it is effective primarily during secondary infections, as attenuated viruses display the envelope proteins (membrane and envelope glycoproteins) using a different viral vector (yellow fever virus) for the host to generate an immune response but may not lead to infection [123]. Here, ERVW-1 is linked to infection.